To determine whether individuals convalescing after COVID-19 produced antibodies with ACE2-like catalytic activity, similar to those we identified in people with acute COVID-19 (43), we studied samples available from 20 individuals from an existing cohort available at the University of Virginia for which plasma samples and clinical testing were available. The gene discussed is ACE2; the disease is COVID-19.